Investor directory

Cybin

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

Top Stages

Acquisition
http://www.cybin.com
https://crunchbase.com/organization/cybin-corp
https://facebook.com/cybininc
https://linkedin.com/company/cybin
https://pitchbook.com/profiles/company/434809-72
https://twitter.com/cybininc
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=666815486

Aaron Bartlone

COO

Paul Glavine

Co-Founder and Director

2 past transactions

Small Pharma

Acquisition in 2023
Small Pharma Ltd. is a pharmaceutical company founded in 2015 and headquartered in London, United Kingdom. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, utilizing expert teams to design and execute development programs. This approach leverages academic discoveries and focuses on effective intellectual property design, ensuring that the various disciplines essential for successful drug development are addressed by qualified professionals.

Adelia Therapeutics

Acquisition in 2020
Adelia Therapeutics, Inc. is a biopharmaceutical company founded in 2020 and located in Fitchburg, Massachusetts. The company focuses on creating a drug discovery platform aimed at developing proprietary tryptamine-based therapeutics specifically for the treatment of central nervous system (CNS) disorders, starting with treatment-resistant depression. Adelia Therapeutics has made advancements in its proprietary therapeutics, enhancing dosing efficacy and therapeutic indices to improve treatment outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.